Zepbound vs Wegovy: what the head-to-head evidence shows

Zepbound and Wegovy are brand names for two different molecules used in obesity care: Zepbound is tirzepatide (Eli Lilly), and Wegovy is semaglutide (Novo Nordisk). They are not two versions of the same drug. The internet usually collapses the comparison into “Zepbound is stronger” — which is roughly true on the one head-to-head obesity average, but skips most of what actually decides which one fits a given person.

This page describes the published evidence. It contains no doses, no titration schedules, and no advice about which to take — those belong to a clinician who knows your history.

How are Zepbound and Wegovy different?

They act on different receptors. Wegovy (semaglutide) is a single GLP-1 receptor agonist. Zepbound (tirzepatide) is a dual agonist — it activates both the GLP-1 receptor and a second one, GIP. Both reduce appetite and slow gastric emptying; the practical question is whether that second target meaningfully changes results, which the trials answer only partway (see below).

They also carry different approved indications, and this is often the deciding factor rather than raw weight loss:

	Zepbound (tirzepatide)	Wegovy (semaglutide)
Maker	Eli Lilly	Novo Nordisk
Mechanism	GLP-1 + GIP dual agonist	GLP-1 receptor agonist
Chronic weight management	Yes (obesity, or overweight + a weight-related condition)	Yes (adults; also ages 12+)
Cardiovascular-event risk reduction	Not an approved indication	Yes — in adults with established cardiovascular disease plus obesity or overweight (based on SELECT)
Obstructive sleep apnea	Yes — moderate-to-severe OSA in adults with obesity (FDA, Dec 2024)	Not an approved indication
Noncirrhotic MASH (liver)	Not an approved indication	Yes — moderate-to-advanced fibrosis (accelerated approval, 2025)
Diabetes “sibling” brand	Mounjaro	Ozempic

Indications change over time; the labels are the authoritative source.

Which one causes more weight loss?

In the single head-to-head obesity trial, SURMOUNT-5, Zepbound produced greater average weight loss than Wegovy. Over 72 weeks in 751 adults with obesity but without diabetes, average body-weight reduction was about 20% with tirzepatide versus about 14% with semaglutide — a statistically significant difference. Tirzepatide also showed larger average improvements in waist circumference and several cardiometabolic markers.

Two honest caveats sit on this result. First, SURMOUNT-5 was open-label — participants and clinicians knew which drug was being given, a recognized limitation for behavior-sensitive outcomes like weight and tolerability. Second, these are group averages: the trial reports what happened across a population, not what will happen to you. That is why the page’s evidence grade is supported but limited — one direct obesity comparison, large and consistent, but not yet the multiple-blinded-trials standard that anchors the top rung of the Evidence Ladder.

It is also worth naming the cardiovascular evidence precisely, because the two differ in kind. Tirzepatide does now have a large cardiovascular-outcomes trial — SURPASS-CVOT (NEJM, December 2025) — but it was an active-comparator non-inferiority study versus another GLP-1 drug (dulaglutide) in people with type 2 diabetes: it found tirzepatide non-inferior for major cardiovascular events, with supportive (secondary) signals toward lower mortality. What tirzepatide does not yet have is a placebo-controlled trial proving it reduces heart attacks, strokes, or deaths in the obesity population — which is exactly what semaglutide (Wegovy) has through SELECT. So “more weight loss,” plus “non-inferior in diabetes,” is still not the same as Wegovy’s placebo-proven event-reduction benefit, and Zepbound does not carry that cardiovascular indication.

Are the side effects different?

Broadly, no — the profiles are similar. Both are dominated by gastrointestinal effects: nausea, vomiting, diarrhea, and constipation, usually worst while the dose is being stepped up and easing over time. In SURMOUNT-5, most adverse events on both drugs were mild to moderate and clustered around dose escalation; gastrointestinal side effects leading to stopping treatment were uncommon on both and were somewhat more frequent with semaglutide (about 5.6%) than tirzepatide (about 2.7%).

Both labels also document the same class of uncommon-but-serious events — pancreatitis, gallbladder disease, and a boxed warning about thyroid C-cell tumors seen in rodents, with a contraindication in people who have a personal or family history of medullary thyroid carcinoma or MEN 2. Neither is recommended in pregnancy.

What does “individual variation” actually mean here?

Trial averages hide a wide spread. In any large weight-loss trial, some people lose far more than the headline figure and some lose little, on both drugs. There is no validated way yet to predict in advance who will respond strongly to Zepbound, who will tolerate Wegovy more easily, or who is a fast versus slow responder. A difference that is real on average — six percentage points in SURMOUNT-5 — may be larger, smaller, or irrelevant for one specific person. Tolerability, existing conditions, cost, insurance coverage, and supply often matter as much as the average efficacy gap.

Frequently asked questions

Is Zepbound just a stronger Wegovy? No. It is a different molecule with a second receptor target. It produced more weight loss on average in the one head-to-head obesity trial, but it is not a higher-dose version of the same drug, and “stronger on average” is not “better for everyone.”

Which has the heart benefit? Wegovy carries an FDA-approved indication to reduce cardiovascular-event risk in adults with established cardiovascular disease plus obesity or overweight, based on the placebo-controlled SELECT trial. Tirzepatide’s cardiovascular trial (SURPASS-CVOT, 2025) was a non-inferiority study versus another drug in type 2 diabetes — reassuring, but not an equivalent placebo-proven event-reduction benefit in the obesity population, and Zepbound does not carry that cardiovascular indication.

Is one better for sleep apnea? Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). Wegovy is not approved for OSA.

If my current drug is working, should I switch to the “stronger” one? That is a clinical decision, not a leaderboard one. If a medicine is working and well tolerated, switching to chase a group-average number has its own trade-offs. Discuss it with your prescriber.

Are compounded or non-prescription versions equivalent? No. The trial evidence here applies to the approved, brand-name medicines used under medical supervision. The same molecule name does not guarantee the same quality, sterility, dose accuracy, or safety.

Questions to ask a clinician

• Given my health profile — cardiovascular history, sleep apnea, liver health, BMI, other conditions — which indication makes one of these a better match for my goals?
• Is a proven cardiovascular-event benefit relevant to me, and does that favor Wegovy?
• If one option is already working and tolerated, is there a real reason to switch?
• What side effects should I expect early, and how will we manage them?
• How do cost, insurance coverage, and supply realistically affect which is sustainable long-term?

Red flags / when to seek care

These are prescription medicines that require medical supervision; the points below are educational, not a substitute for your clinician or emergency services.

• Severe, persistent abdominal pain, especially radiating to the back and with vomiting — possible pancreatitis; seek urgent care.
• Upper-right abdominal pain, fever, or yellowing of the skin or eyes — possible gallbladder disease.
• Signs of dehydration from prolonged vomiting or diarrhea, or an inability to keep fluids down.
• Swelling of the face, lips, or throat, or trouble breathing — a possible severe allergic reaction and a medical emergency.
• Any marketing claim that one brand is simply “stronger and therefore better for everyone,” or any offer to supply either drug without a prescribing clinician, is a reason to step back: the comparison that matters is the one made with someone who knows your history.